The biotech has been evaluating 50-mg and 100-mg daily doses of its cardiac sarcomere modulator, dubbed EDG-7500, in a four-week, open-label phase 2 Cirrus-HCM trial of patients with obstructive ...

cardiac events." The study analyzed 107 unrelated HCM patients using advanced exome-based gene panels, drawing from diverse populations including Ashkenazi Jews, Muslim Arabs, and North African ...

the CNIC team developed a gene therapy using adeno-associated viruses (AAV)—a safe delivery system for human patients—to deliver a functional copy of TMEM43 directly into the cardiac muscle ...

18, 2025 — New research suggests that decreased activity of ELOVL2 -- a key enzyme in lipid metabolism -- accelerates white blood cell aging and alters genes associated with the onset of blood ...

In diabetes, the function of the sarcomere structural protein MyBPC3 (myosin-binding protein C3) is impaired by ACBP, causing a reduction in cross-bridge structure and a decrease in cardiac ...

Bayer’s AskBio gene therapy unit has started recruiting patients into a phase 2 trial of its AB-1002 candidate for congestive heart failure (CHF), buoyed by encouraging data from a first-in ...

Bayer’s AskBio unit has reported the first clinical data for its congestive heart failure gene therapy, showing preliminary signs of efficacy with no serious adverse events linked to the treatment.